News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 644 results
November 2015
-
Media ReleaseNovartis heart failure medicine Entresto™ substantially cuts 30-day hospital readmissions, new post-hoc analysis showsFollowing a heart failure hospitalization, 44% fewer patients treated with Entresto were readmitted for heart failure, and 36% fewer patients were readmitted for any cause, within 30 days compared to…
-
Media ReleaseNovartis heart failure medicine Entresto™ substantially cuts 30-day hospital readmissions, new post-hoc analysis shows
-
Media ReleaseUp to 80% of ankylosing spondylitis patients treated with Cosentyx® show no spinal x-ray progression as shown in Novartis new two-year observational data- 104 Week sub-analysis data from the Cosentyx Phase III Measure 1 study in patients with ankylosing spondylitis (AS) presented at ACR 2015(1,2)- Two-year x-ray data from observational sub-analysis…
-
Media ReleaseApproximately 80% of psoriatic arthritis patients treated with Cosentyx® saw no progression of joint damage as shown in Novartis new two-year observational data- 104 Week sub-analysis data from the Cosentyx Phase III FUTURE 1 trial in patients with psoriatic arthritis (PsA) presented at ACR 2015(1,2)- Patients receiving Cosentyx through 104 weeks maintained…
-
Media ReleaseUp to 80% of ankylosing spondylitis patients treated with Cosentyx® show no spinal x-ray progression as shown in Novartis new two-year observational data
-
Media ReleaseApproximately 80% of psoriatic arthritis patients treated with Cosentyx® saw no progression of joint damage as shown in Novartis new two-year observational data
October 2015
-
Media ReleaseFDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler® for patients with chronic obstructive pulmonary disease- Utibron Neohaler (indacaterol/glycopyrrolate) demonstrated superior and sustained improvements in lung function compared to either of its single bronchodilator components as well as placebo, and…
-
Media ReleaseFDA approves new Novartis dual combination bronchodilator Utibron™ Neohaler® for patients with chronic obstructive pulmonary disease
-
Media ReleaseNovartis Clarification on Specialty Pharmacy Settlement in Principle AnnouncementAs part of Q3 Earnings, Novartis announced that it reached a settlement in principle in the suit related to the Company's interactions with specialty pharmacies. Some media coverage did not…
-
Media ReleaseNovartis Clarification on Specialty Pharmacy Settlement in Principle Announcement
September 2015
-
Media ReleaseNovartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis-- In the FUTURE 1 study, secukinumab met the primary endpoint showing statistically significant efficacy versus placebo in improving signs and symptoms of active psoriatic arthritis (PsA)-- All pre-…
-
Media ReleaseNovartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis
Pagination
- ‹ Previous page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- …
- 54
- › Next page